APA (7th ed.) Citation

Masri, A., Barriales‐Villa, R., Elliott, P., Nassif, M. E., Oreziak, A., Owens, A. T., . . . Saberi, S. (2024). Safety and efficacy of aficamten in patients with non‐obstructive hypertrophic cardiomyopathy: A 36‐week analysis from FOREST‐HCM. European Journal of Heart Failure, 26(9), 1993. https://doi.org/10.1002/ejhf.3372

Chicago Style (17th ed.) Citation

Masri, Ahmad, et al. "Safety and Efficacy of Aficamten in Patients with Non‐obstructive Hypertrophic Cardiomyopathy: A 36‐week Analysis from FOREST‐HCM." European Journal of Heart Failure 26, no. 9 (2024): 1993. https://doi.org/10.1002/ejhf.3372.

MLA (9th ed.) Citation

Masri, Ahmad, et al. "Safety and Efficacy of Aficamten in Patients with Non‐obstructive Hypertrophic Cardiomyopathy: A 36‐week Analysis from FOREST‐HCM." European Journal of Heart Failure, vol. 26, no. 9, 2024, p. 1993, https://doi.org/10.1002/ejhf.3372.